Helix Biopharma Stock Price To Earnings To Growth
| HBP Stock | EUR 1.15 0.00 0.00% |
HELIX BIOPHARMA fundamentals help investors to digest information that contributes to HELIX BIOPHARMA's financial success or failures. It also enables traders to predict the movement of HELIX Stock. The fundamental analysis module provides a way to measure HELIX BIOPHARMA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HELIX BIOPHARMA stock.
HELIX |
HELIX BIOPHARMA Company Price To Earnings To Growth Analysis
HELIX BIOPHARMA's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, HELIX BIOPHARMA has a Price To Earnings To Growth of 0.0 times. This indicator is about the same for the Other average (which is currently at 0.0) sector and about the same as Other (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
| All Next | Launch Module |
HELIX Fundamentals
| Current Valuation | 29.03 M | |||
| Price To Book | 50.71 X | |||
| EBITDA | (6.53 M) | |||
| Net Income | (6.56 M) | |||
| Cash Flow From Operations | (6.51 M) | |||
| Number Of Employees | 13 | |||
| Market Capitalization | 38.94 M | |||
| Total Asset | 3.73 M | |||
| Z Score | -3.3 | |||
| Net Asset | 3.73 M |
About HELIX BIOPHARMA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HELIX BIOPHARMA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HELIX BIOPHARMA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HELIX BIOPHARMA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for HELIX Stock Analysis
When running HELIX BIOPHARMA's price analysis, check to measure HELIX BIOPHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HELIX BIOPHARMA is operating at the current time. Most of HELIX BIOPHARMA's value examination focuses on studying past and present price action to predict the probability of HELIX BIOPHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HELIX BIOPHARMA's price. Additionally, you may evaluate how the addition of HELIX BIOPHARMA to your portfolios can decrease your overall portfolio volatility.